权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Credentialing Mouse Models for Immune System Therapy Research

免疫系统治疗研究小鼠模型的认证

基本信息

批准号：
8903941
负责人：
CHARLES M. PEROU
金额：
$ 58.9万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-06-12 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8903941
关键词：
Aftercare Animal Model Animals Antibodies Area B-Lymphocytes Basic Science Bioinformatics Biological Assay Biological Markers Biological Models Biology Breast Breast Cancer Model Breast Cancer gene Breast Carcinoma CD4 Positive T Lymphocytes CD8B1 gene CTLA4 gene Cancer Biology Carboplatin Cell Line Cells Cellular Structures Characteristics Clinical Clinical Trials Comparative Genomic Analysis Complex Coupled Credentialing Cyclophosphamide Data Databases Disease Progression Dose Endothelial Cells Environment Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epithelial Epithelial Cells Fibroblasts Gene Expression Gene Expression Profiling Gene Proteins Genes Genetically Engineered Mouse Genomics Goals Human Human Cell Line Immune Immune system Immunotherapy Individual Libraries Link Lung Lung Adenocarcinoma Malignant Neoplasms Malignant neoplasm of lung Mammary Neoplasms Mammary gland Messenger RNA Methodology Methods Modeling Molecular Profiling Monitor Mus Paclitaxel Patients Pharmaceutical Preparations Pre-Clinical Model Predictive Value Regimen Research Personnel Resistance Schedule Solid Neoplasm Sorting - Cell Movement T-Lymphocyte Testing The Cancer Genome Atlas Therapeutic Therapeutic Clinical Trial Therapeutic Studies Translational Research Tumor Subtype Tumor-Derived Validation Variant Xenograft Model Xenograft procedure base body system comparative disorder subtype genome-wide human data human disease in vivo inhibitor/antagonist kinase inhibitor macrophage malignant breast neoplasm member mouse model novel oncology pre-clinical public health relevance response treatment response tumor tumor xenograft validation studies

项目摘要

DESCRIPTION (provided by applicant): The use of animal models for preclinical therapeutic testing is a powerful approach, if the model(s) used are accurate mimics of the human disease in question. Many researchers have used histological assessments of tumors coming from Genetically Engineered Mice (GEM) as a means of linking specific mouse models to known human disease subtypes. We have developed a complementary approach based upon genome-wide gene expression profiling where we objectively compare the genomic profiles of mouse tumors coming from a given organ system (i.e. breast) versus human tumor profiles, and have been able identify specific GEM models which best mimic human disease subtypes. We propose to continue and extend these genomic validation studies to include additional models of breast carcinoma and to extend our studies to models of lung cancer with the goal of using the most appropriate models for pre- clinical therapeutic trials of immune checkpoint inhibitors given the tremendous clinical importance in this area. GEM models present an advantage over other pre-clinical models like PDX or human cell line models in that they are host is immunologically intact. We propose to study the immune microenvironment in these GEM models to identify mechanisms of immune evasion and predictive signatures for response to immune checkpoint inhibitors that can ultimately be applied to human clinical trials.

描述（由申请方提供）：如果所用模型准确模拟了所讨论的人类疾病，则使用动物模型进行临床前治疗试验是一种有效的方法。许多研究人员使用来自遗传工程小鼠（GEM）的肿瘤的组织学评估作为将特定小鼠模型与已知人类疾病亚型联系起来的手段。我们已经开发了一种基于全基因组基因表达谱的互补方法，其中我们客观地比较了来自给定器官系统（即乳腺）的小鼠肿瘤的基因组谱与人类肿瘤谱，并且已经能够鉴定出最能模拟人类疾病亚型的特定GEM模型。我们建议继续并扩展这些基因组验证研究，以包括乳腺癌的其他模型，并将我们的研究扩展到肺癌模型，目标是使用最合适的模型进行免疫检查点抑制剂的临床前治疗试验，因为该领域具有巨大的临床重要性。GEM模型比其他临床前模型如PDX或人细胞系模型具有优势，因为它们是免疫完整的宿主。我们建议研究这些GEM模型中的免疫微环境，以确定免疫逃避机制和对免疫检查点抑制剂的反应的预测特征，这些免疫检查点抑制剂最终可应用于人体临床试验。